More Company News

MaxCyte

Apeiron Biologics clinical and commercial licence
08 Jul 2020Read More

MaxCyte

Result of special meeting and issue of equity
21 May 2020Read More

MaxCyte

MCY-M11 poster to be presented at ASCO 2020
14 May 2020Read More

MaxCyte

License agreement with Caribou Biosciences
07 May 2020Read More

MaxCyte

Result of offering
01 May 2020Read More

MaxCyte

Proposed offering to raise up to £25.1m
30 Apr 2020Read More

MaxCyte

FY19 results
21 Apr 2020Read More

MaxCyte

Business update related to COVID-19 pandemic
09 Apr 2020Read More

MaxCyte

Licence agreement with Allogene Therapeutics
24 Mar 2020Read More

MaxCyte

FY19 trading update
20 Jan 2020Read More

1 2 3 4 … 6
Return to MaxCyte
© 2019-20 Trinity Delta. All rights reserved. Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).